Is NCT05994482 recruiting in West Los Angeles, CA?

Yes, NCT05994482 is currently recruiting participants at its West Los Angeles, CA location. This colorectal cancer clinical trial is actively enrolling qualified participants.

How do I join the colorectal cancer clinical trial in West Los Angeles?

To join this clinical trial in West Los Angeles, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this West Los Angeles clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Colorectal Cancer Clinical Trial in West Los Angeles, CA

About This Colorectal Cancer Study in West Los Angeles

Colorectal cancer is a leading cause of cancer death. Detection and removal of polyps can reduce risk for developing colorectal cancer. After finding and removing precancerous polyps, repeat colonoscopy is routinely recommended. However, it is unclear whether repeat additional colonoscopy further reduces risk for colorectal cancer. For older adults age 75 and older, the lack of this information is especially important, given that the risks of colonoscopy go up with age. This research will evaluate whether older adults with a prior history of precancerous polyps have higher colorectal cancer risks compared to older adults who had a prior normal colonoscopy, and whether, among those with prior precancerous polyps, repeating a colonoscopy after age 75 is associated with reduced cancer risk. The investigators will synthesize these data and gather perspectives from Veterans and clinical stakeholders to make recommendations on whether older adults with a prior history of polyps should continue or defer colonoscopy after age 75.

Sponsor: VA Office of Research and Development

Who Can Participate

Inclusion Criteria

Study Base and Inclusion Criteria, Aim 1:

The study base will consist of any Veteran alive at age 75 between 2005-2019, with exposure to a qualifying colonoscopy in the 10-year period prior to turning age 75

The investigators will include those with a qualifying colonoscopy associated with a colonoscopy note that can be processed by the previously established natural language processing (NLP) pipelines for extracting colonoscopy data from free-text reports60, 61 (see prior work below)

The colonoscopy done closest to, but prior to age 75 will be considered as a candidate qualifying colonoscopy

Date of cohort entry (start of follow up) will be defined as date at which a participant meeting inclusion criteria turned 75

Date of qualifying colonoscopy prior to age 75 will be defined as the qualifying colonoscopy reference date Study Base and Inclusion Criteria for Cases and Subcohort, Aim 2:

The study base for Aim 2 consists of Veterans ages 75 and alive between 2003-2019 who had a polypectomy prior to turning age 75

Identification of the study base for Aim 2 will take a distinct approach from Aim 1

A candidate qualifying colonoscopy event will be defined by presence of a CPT code for colonoscopy associated with a pathology note-based diagnosis of an adenoma within 30 days of the CPT code for colonoscopy

The colonoscopy event occurring closest to, but prior to age 75 will be selected

From the study base, all individuals who developed incident or fatal CRC, and a random sample of the entire study base will undergo manual EHR chart review to confirm study eligibility

To identify candidate incident CRC cases, the investigators will identify all adults with a CRC diagnosis at ages 75, utilizing the Oncology Domain with the same strategy for incident CRC identification as described for Aim 1

To identify candidate fatal CRC cases, the investigators will identify all adults with a fatal CRC diagnosis at ages 75, using NDI cause-specific mortality data

To identify candidate members of the subcohort for chart review, a random sample of the study base will be drawn

This sample may include Veterans with and without subsequent CRC. Rationale for including Veterans with and without subsequent CRC (incident and/or fatal) in the control subcohort is well established

Specifically, if the investigators were to conduct a cohort study without sampling, then at the start of follow up, the cohort would include people with subsequent CRC

In a traditional cohort study, every CRC case contributes to the denominator of individuals at risk. Thus, by including in the subcohort Veterans with and without CRC on follow up, the investigators are able to calculate risk based on exposure to surveillance as if the investigators had conducted a cohort study utilizing the entire cohort Inclusion Criteria, Aim 3a: Participant selection for qualitative interviews. Patient Selection:

The investigators will use EHR data to generate a list of VASDHS and VAGLA patients who have:

b) history of colonoscopy with polypectomy in the past 10 years

c) been referred for surveillance colonoscopy

The investigators will randomly select patients, recruiting until the investigators have 12 who completed surveillance colonoscopy and 12 who have not completed surveillance

The investigators will monitor the sample to assure sex balance consistent with VA demographics for patients who have had colonoscopy (98.2% male and 1.8% females age 75)

The investigators will also ensure that at least one- third of sampled patients have moderate or severe frailty based on the claims-based VA-FI36, 64 and make efforts to maintain patient racial/ethnic and geographic (i.e. San Diego/Los Angeles areas) diversity Provider Selection:

The investigators will conduct interviews with 20 providers, specifically 10 primary care providers (including 3-4 geriatricians) and 10 gastroenterologists

The investigators will select providers from a randomly generated list of practicing VA clinicians (5/8th or greater) at VASDHS or VAGLA

If the investigators experience challenges reaching the target sample size, the investigators will employ snowball sampling by asking participants to name other potentially eligible clinicians

The investigators anticipate reaching thematic saturation given \> 17 interviews in each group and have made provisions to accommodate up to 6 additional patient and/or provider interviews if new themes continue to arise by the end of the planned interviews

The investigators will make efforts to achieve geographic balance to ensure provider representation from VASDHS and VAGLA Participant selection for expert panel:

The investigators will convene a group of 15-20 multi-level stakeholders for the in-person expert panel in Quarter 1 of Year 4

The panel will include VA patients and caregivers (not included in Aim 3a):

VA providers

VA leadership and policymakers

health services and clinical researchers

individuals with non-VA healthcare systems perspectives

Exclusion Criteria

Study Base and Exclusion Criteria, Aim 1:

History of CRC prior to age 75

History of sessile serrated adenoma/polyp/lesion (SSL), traditional serrated adenoma (TSA), or large serrated polyp (LSP, defined as hyperplastic polyp \>10mm) at qualifying colonoscopy

History of inflammatory bowel disease (IBD) prior to age 75

Absence of exposure to normal colonoscopy or colonoscopy with polypectomy between ages 65-75 Study Base and Exclusion Criteria for Cases and Subcohort, Aim 2:

All candidate CRC cases and members for the subcohort will be included in the analytic sample unless they meet one of the following exclusion criteria:

absence of a reviewable colonoscopy note

absence of polypectomy with adenoma diagnosis at candidate qualifying colonoscopy event

presence of a SSL, TSA, or LSP

history of CRC or IBD

history of hereditary cancer syndrome (this criteria is not used for Aim 1 because it cannot be reliably assessed with structured EHR data)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in West Los Angeles?

Yes, this clinical trial (NCT05994482) has an active research site in West Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Colorectal Cancer Treatment Options in West Los Angeles, CA

If you're searching for colorectal cancer treatment options in West Los Angeles, CA, this clinical trial (NCT05994482) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our West Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all colorectal cancer clinical trials near you to find additional studies recruiting in your area.

Colorectal Cancer Clinical Trial in West Los Angeles, CA

Expert Care in West Los Angeles

IRB Approved

No-Cost Care

Apply for This West Los Angeles Location

Why Participate?

Simple Process